Welcome to LookChem.com Sign In|Join Free

CAS

  • or

14804-61-6

Post Buying Request

14804-61-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

14804-61-6 Usage

Description

1-(1-bromoethyl)-4-chlorobenzene, with the molecular formula C8H8BrCl, is a colorless liquid at room temperature. It is a chemical compound that serves as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Additionally, it is utilized as a solvent and in research applications. Due to its moderate toxicity and potential to irritate the skin and eyes, it requires careful handling and storage with appropriate safety measures to mitigate exposure and health risks.

Uses

Used in Pharmaceutical Synthesis:
1-(1-bromoethyl)-4-chlorobenzene is used as a chemical intermediate for the production of various pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of drugs, contributing to the development of new medications and therapies.
Used in Organic Compound Synthesis:
1-(1-bromoethyl)-4-chlorobenzene is also utilized as an intermediate in the synthesis of other organic compounds, playing a crucial role in the creation of a wide range of chemical products.
Used as a Solvent:
1-(1-bromoethyl)-4-chlorobenzene is employed as a solvent in various chemical processes. Its properties make it suitable for dissolving certain substances, facilitating reactions, and aiding in the production of desired products.
Used in Research Applications:
In the field of scientific research, 1-(1-bromoethyl)-4-chlorobenzene is used for various experimental purposes. It helps researchers in understanding chemical reactions, testing hypotheses, and developing new methodologies in organic chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 14804-61-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,8,0 and 4 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 14804-61:
(7*1)+(6*4)+(5*8)+(4*0)+(3*4)+(2*6)+(1*1)=96
96 % 10 = 6
So 14804-61-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H8BrCl/c1-6(9)7-2-4-8(10)5-3-7/h2-6H,1H3

14804-61-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(1-Bromoethyl)-4-chlorobenzene

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:14804-61-6 SDS

14804-61-6Relevant articles and documents

Pharmacological characterization of [3H]VUF11211, a novel radiolabeled small-molecule inverse agonist for the chemokine receptor CXCR3

Scholten, Danny J.,Wijtmans, Maikel,Van Senten, Jeffrey R.,Custers, Hans,Stunnenberg, Ailas,De Esch, Iwan J. P.,Smit, Martine J.,Leurs, Rob

, p. 639 - 648 (2015)

Chemokine receptor CXCR3 has attracted much attention, as it is thought to be associated with a wide range of immunerelated diseases. As such, several small molecules with different chemical structures targeting CXCR3 have been discovered. Despite limited clinical success so far, these compounds serve as interesting tools for investigating receptor activation and antagonism. Accumulating evidence suggests that many of these compounds are allosteric modulators for CXCR3. One feature of allosteric ligands is that the magnitude of the mediated allosteric effect is dependent on the orthosteric probe that is used. Consequently, there is a risk for incorrect assessment of affinity for allosteric modulators with orthosteric radioligands, which has so far been the most applied approach for chemokine receptors. Therefore, we aimed to use a small-molecule allosteric ligand from the piperazinyl-piperidine class, also known as VUF11211 [(S)-5- chloro-6-(4-(1-(4-chlorobenzyl)piperidin-4-yl)-3-ethylpiperazin- 1-yl)-N-ethylnicotinamide]. VUF11211 acts as an inverse agonist at a constitutively active mutant of CXCR3. Radiolabeling of VUF11211 gave [3H]VUF11211, which in radioligand binding studies shows high affinity for CXCR3 (Kd 5 0.65 nM) and reasonably fast association (kon5 0.03 minute-1nM21) and dissociation kinetics (koff 5 0.02 minute21). The application of the [3H]VUF11211 to assess CXCR3 pharmacology was validated with diverse classes of CXCR3 compounds, including both antagonists and agonists, as well as VUF11211 analogs. Interestingly, VUF11211 seems to bind to a different population of CXCR3 conformations compared with the CXCR3 agonists CXC chemokine ligand 11 (CXCL11), VUF11418 [1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)- N-((29-iodobiphenyl-4-yl)methyl)-N,N-dimethylmethanaminium Iodide], and VUF10661 [N-(6- Amino-1-(2,2-diphenylethylamino)- 1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4- Tetrahydroisoquinoline- 3-carboxamide]. These findings, taken together, indicate that this allosteric inverse agonist radioligand for CXCR3 may facilitate the discovery, characterization, and optimization of allosteric modulators for the chemokine receptor CXCR3.

SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES

-

Paragraph 0069, (2021/02/19)

A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione analogues, the use thereof and the preparation thereof.

SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE

-

Paragraph 0652, (2017/04/04)

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 14804-61-6